Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vernalis completes its detour

Most investors gave Vernalis plc up for a goner after the company began to run out of money in 2002 and Roche dropped its option to license an adenosine A2A antagonist program to treat depression in 2003. By mid-2003, Vernalis was left with £17.8 million ($29.6 million) in cash and obligations to pay out £22 million ($36 million) over the next two years to partner Elan Corp. plc to help pay for further trials of migraine drug Frova frovatriptan.

The company began

Read the full 825 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE